瑞舒伐他汀与阿托伐他汀强化降脂治疗急性脑梗死疗效及安全性比较

Efficacy and safety of rosuvastatin and atorvastatin in the treatment of acute cerebral infarction

目的探讨与比较瑞舒伐他汀与阿托伐他汀强化降脂治疗急性脑梗死的疗效及安全性为临床用药物的选择提供参考依据。方法收集2016年2月—2017年2月入院的80例急性脑梗塞患者随机分为两组,观察组予以瑞舒伐他汀治疗,对照组予以阿托伐他汀治疗,比较两组神经缺损、生活能力评分、总体治疗效果、血脂、空腹血糖、血流速度、血流变指标与不良反应。计量资料比较采用t检验,计数资料比较采用χ~2检验,P<0.05为差异有统计学意义。结果治疗后,观察组NIHSS评分、TC、TG、全血高切粘度、全血低切粘度与红细胞比容低于对照组,BI指数、ACA、MCA与PCA高于对照组,差异有统计学意义(均P<0.05)。观察组显效率及总有效率高于对照组,差异有统计学意义(均P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论与阿托伐他汀相比,瑞舒伐他汀强化降脂治疗急性脑梗死的疗效显著,且安全性较高。

Objective To investigate the efficacy and safety of rosuvastatin and atorvastatin in the treatment of acute cerebral infarction providing a reference basis for the selection of clinical medication.Methods Eighty patients with acute cerebral infarction admitted from February 2016 to February 2017 were randomly divided into two groups.Patients in the observation group were treated with rosuvastatin and the control group was treated with atorvastatin.Nerve defects,life ability score,the overall clinical effect,blood lipids,fasting blood glucose,blood flow velocity,blood rheology indicators and adverse reactions of the two groups were detected and compared.Measurement data were compared by t test and enumeration data were compared by χ~2 test.P〈0.05 was considered statistically significant.Results Compared with the control group,the scores of NIHSS,TC,TG,whole blood high shear viscosity,whole blood low shear viscosity and erythrocyte volume were lower in the observation group.The BI index,ACA,MCA and PCA were higher in the observation group（all P〈0.05）.The significant efficiency and total effective rate of the observation group were higher than that of the control group（all P〈0.05）.There was no significant difference in the incidence of adverse reactions between the two groups（P〉0.05）.Conclusion Compared with atorvastatin,rosuvastatin enhanced the effect of lipid-lowering therapy on acute cerebral infarction with high safety.